MedTrace Logo

A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients

NCT06732960 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-02

No results posted yet for this study

Summary

This is a study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa at difference dose range once-weekly in patients with Overweight or Obesity.

Conditions

  • Overweight or Obesity

Interventions

BIOLOGICAL

Efsubaglutide Alfa

Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.

OTHER

Placebo

Placebo subcutaneous injection weekly

Sponsors & Collaborators

  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital

    collaborator OTHER

  • Beijing Friendship Hospital

    collaborator OTHER

  • Jinan Central Hospital

    collaborator OTHER

  • Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

    lead OTHER

Principal Investigators

  • Weiping Jia, M.D,Ph. D · Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-21
Primary Completion
2024-11-18
Completion
2024-11-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06732960 on ClinicalTrials.gov